Does visceral fat area (VFA) have predictive value for hypertension (HTN) and progression-free survival (PFS) in patients (pts) with stage IV NSCLC receiving bevacizumab (Beva)?
O. Mir
Consultant or Advisory Role - Roche (U); SERVIER (U)
R. Coriat
No relevant relationships to disclose
S. Ropert
Consultant or Advisory Role - Roche (U)
J. Chapron
No relevant relationships to disclose
P. Boudou-Rouquette
No relevant relationships to disclose
J. Durand
Consultant or Advisory Role - Merck (U)
T. Bui
No relevant relationships to disclose
D. Dusser
No relevant relationships to disclose
F. Goldwasser
Consultant or Advisory Role - Amgen (U); Bayer (U); Pfizer (U)